Asia Pacific Contrast Injector Systems Market Size to reach a market to register a growth of 9.1% CAGR

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

According to a new report Asia Pacific Contrast Injector Systems Market, published by KBV research, the Asia Pacific Contrast Injector Systems Market would witness market growth of 9.1% CAGR during the forecast period (2018 – 2024).

The Hospitals market dominated the India Contrast Injector Systems Market by End User in 2017. The Diagnostics Centers market is expected to witness a CAGR of 10.1% during (2018 - 2024).

The Japan market dominated the Asia Pacific Injector Systems Market by 2024, growing at a CAGR of 8.4 % during the forecast period. The China market is expected to witness a CAGR of 8.5% during (2018 - 2024). Additionally, The India market is expected to witness a CAGR of 11.2% during (2018 - 2024).

The Radiology market would dominate the Asia Pacific Contrast Injector Systems Market and would achieve a market value of $102.3 million by 2024. The Interventional Radiology market is expected to witness a CAGR of 8.8% during (2018 - 2024).

Full Report: https://www.kbvresearch.com/asia-pacific-contrast-injector-systems-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bayer Ag, Angiodynamics Inc., GE Healthcare (A Healthcare Division of GE Company), Medtron AG, Nemoto Kyorindo Co., Ltd., Sino Medical- Device Technology Co., Ltd., Shenzhen Seacrown Electromechanical Co., Ltd., Ulrich GmbH & Co. Kg, Vivid Imaging and Guerbet Group.